The European Medicines Agency has proposed revising its five-year old guideline on medicinal products containing genetically-modified cells to primarily address the availability of improved genome editing technologies and to incorporate quality, non-clinical and clinical issues specific to chimeric antigen receptor (CAR)-T cells.
The proposed changes are outlined in a concept paper in which the EMA notes that its existing guideline...








